ICL670A: preclinical profile.
Nick
Hanspeter
H
Novartis Pharma AG, 4002 Basel, Switzerland.
Wong
Agnes
A
Acklin
Pierre
P
Faller
Bernard
B
Jin
Yi
Y
Lattmann
René
R
Sergejew
Thomas
T
Hauffe
Suzanne
S
Thomas
Helmut
H
Schnebli
Hans Peter
HP
D000284:Administration, Oral; D000818:Animals; D001565:Benzoates / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D002144:Callithrix; D000077588:Deferasirox; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D019190:Iron Overload / Q000188:drug therapy / Q000378:metabolism; D015394:Molecular Structure; D051381:Rats; D014230:Triazoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D017086:beta-Thalassemia / Q000188:drug therapy
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D007501:Iron; D000077588:Deferasirox